R. Gold

615 total citations
20 papers, 448 citations indexed

About

R. Gold is a scholar working on Neurology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, R. Gold has authored 20 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 7 papers in Immunology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in R. Gold's work include Peripheral Neuropathies and Disorders (9 papers), Multiple Sclerosis Research Studies (5 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). R. Gold is often cited by papers focused on Peripheral Neuropathies and Disorders (9 papers), Multiple Sclerosis Research Studies (5 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). R. Gold collaborates with scholars based in Germany, United Kingdom and United States. R. Gold's co-authors include Martin Stangel, Hans‐Peter Hartung, Harald H. Hofstetter, Peter Marx, Klaus V. Toyka, Uwe K. Zettl, H. Wekerle, Andrew Chan, Joseli Lannes-Vieira and Kreutzberg Gw and has published in prestigious journals such as Acta Neuropathologica, Current Pharmaceutical Design and Journal of Neuroimmunology.

In The Last Decade

R. Gold

20 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Gold Germany 12 180 147 112 103 74 20 448
Verena I. Leussink Germany 14 229 1.3× 162 1.1× 61 0.5× 331 3.2× 46 0.6× 20 591
Rosaria Leante Italy 5 204 1.1× 38 0.3× 78 0.7× 63 0.6× 37 0.5× 5 398
Sonja Ortler Germany 10 55 0.3× 219 1.5× 43 0.4× 96 0.9× 89 1.2× 17 399
Casey MM Pfluger Australia 9 201 1.1× 133 0.9× 25 0.2× 106 1.0× 69 0.9× 11 428
Koichi Miyagi Japan 11 68 0.4× 131 0.9× 24 0.2× 108 1.0× 62 0.8× 16 347
Jitesh Rana United States 4 82 0.5× 123 0.8× 36 0.3× 247 2.4× 34 0.5× 10 382
Andrea Viehöver Germany 7 75 0.4× 304 2.1× 111 1.0× 233 2.3× 65 0.9× 10 648
Y.K Semra United Kingdom 14 121 0.7× 214 1.5× 36 0.3× 258 2.5× 40 0.5× 19 606
Joakim Bergman Sweden 6 145 0.8× 79 0.5× 21 0.2× 186 1.8× 41 0.6× 8 348
Shoana L. Sikorski United States 4 35 0.2× 72 0.5× 106 0.9× 51 0.5× 128 1.7× 5 543

Countries citing papers authored by R. Gold

Since Specialization
Citations

This map shows the geographic impact of R. Gold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Gold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Gold more than expected).

Fields of papers citing papers by R. Gold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Gold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Gold. The network helps show where R. Gold may publish in the future.

Co-authorship network of co-authors of R. Gold

This figure shows the co-authorship network connecting the top 25 collaborators of R. Gold. A scholar is included among the top collaborators of R. Gold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Gold. R. Gold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gass, Achim, M. Haupts, Carsten Lukas, et al.. (2015). Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose. Nervenheilkunde. 34(11). 915–923. 3 indexed citations
2.
Chan, Andrew, R. Gold, & Nicolas von Ahsen. (2011). ATP-Binding Cassette Transporters in Inflammatory Brain Disease. Current Pharmaceutical Design. 17(26). 2803–2807. 4 indexed citations
3.
Hofstetter, Harald H., et al.. (2009). Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis.. PubMed. 16(1). 12–8. 65 indexed citations
4.
Stangel, Martin & R. Gold. (2007). Einsatz intravenöser Immunglobuline in der Neurologie: Aktuelle Entwicklungen. Aktuelle Neurologie. 34(6). 342–347. 1 indexed citations
5.
Stangel, Martin & R. Gold. (2005). Intravenous Immunoglobulins in MS.. PubMed. 12(1). 5–10, 4. 15 indexed citations
6.
Stangel, Martin & R. Gold. (2004). [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].. Der Nervenarzt. 75(8). 801–15. 11 indexed citations
7.
Leussink, Verena I., D. Brechtelsbauer, Martin Bendszus, et al.. (2003). Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurologica Scandinavica. 107(1). 54–61. 36 indexed citations
8.
Weilbach, F. X., Andrew Chan, K. V. Toyka, & R. Gold. (2003). The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clinical & Experimental Immunology. 135(1). 49–55. 33 indexed citations
9.
Leussink, Verena I., Uwe K. Zettl, Sebastian Jander, et al.. (2002). Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathologica. 103(2). 131–136. 43 indexed citations
10.
Hadden, Robert D. M., Norman A. Gregson, R. Gold, Kenneth J. Smith, & Richard AC Hughes. (2002). Accumulation of immunoglobulin across the ‘blood–nerve barrier’ in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathology and Applied Neurobiology. 28(6). 489–497. 31 indexed citations
11.
Hadden, Robert D. M., N. A. Gregson, R. Gold, Hugh J. Willison, & Richard AC Hughes. (2001). Guillain–Barré syndrome serum and anti-Campylobacter antibody do not exacerbate experimental autoimmune neuritis. Journal of Neuroimmunology. 119(2). 306–316. 13 indexed citations
12.
Storch, Maria K., et al.. (1999). The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy.. PubMed. 111(17). 728–37. 1 indexed citations
13.
Chan, Andrew, R. Gold, Gerhard Giegerich, et al.. (1999). Usage of v?3.3 T-cell receptor by myelin basic protein-specific encephalitogenic T-cell lines in the Lewis rat. Journal of Neuroscience Research. 58(2). 214–225. 9 indexed citations
14.
Stangel, Martin & R. Gold. (1997). Treatment with Intravenous Immunoglobulins in Critical Care of Neuromuscular Disorders. Transfusion Medicine and Hemotherapy. 24(3). 171–177. 1 indexed citations
15.
Stangel, Martin, Hans‐Peter Hartung, Peter Marx, & R. Gold. (1997). Side Effects of High-Dose Intravenous Immunoglobulins. Clinical Neuropharmacology. 20(5). 385–393. 58 indexed citations
16.
Zettl, Uwe K., R. Gold, Klaus V. Toyka, & Hans‐Peter Hartung. (1996). In situ demonstration of T cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat. Acta Neuropathologica. 91(4). 360–367. 36 indexed citations
17.
Hp, Hartung, et al.. (1996). Autoimmunity in the peripheral nervous system.. PubMed. 5(1). 1–45. 14 indexed citations
18.
Gold, R.. (1996). Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat. Journal of Neuroimmunology. 69(1-2). 157–164. 5 indexed citations
19.
Gold, R., H.‐P. Hartung, & K. V. Toyka. (1995). Therapie mit Immunglobulinen bei neurologischen Autoimmunerkrankungen. Fortschritte der Neurologie · Psychiatrie. 63(1). 17–29. 5 indexed citations
20.
Gehrmann, Jochen, R. Gold, Christopher Linington, et al.. (1992). Spinal cord microglia in experimental allergic neuritis. Evidence for fast and remote activation.. PubMed. 67(1). 100–13. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Verena I. Leussink Breakdown of academic impact, for papers by Rosaria Leante Breakdown of academic impact, for papers by Sonja Ortler Breakdown of academic impact, for papers by Casey MM Pfluger Breakdown of academic impact, for papers by Koichi Miyagi Breakdown of academic impact, for papers by Jitesh Rana Breakdown of academic impact, for papers by Andrea Viehöver Breakdown of academic impact, for papers by Y.K Semra Breakdown of academic impact, for papers by Joakim Bergman Breakdown of academic impact, for papers by Shoana L. Sikorski
Rankless by CCL
2026